๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Advanced/Metastatic Breast Cancer

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor NCT05933395Phase 21 site๐Ÿ“ Lebanon Dartmouth-Hitchcock Medical Center ยท Tests: Fulvestrant, Neratinib, Alpelisib, Everolimus, Abemaciclib Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer NCT07563595n/a3 sites๐Ÿ“ Freiburg im Breisgau๐Ÿ“ Paderborn๐Ÿ“ Ravensburg iOMEDICO AG ยท Tests: Elacestrant, Standard of care (Investigator Choice) Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. NCT05378204NA25 sites๐Ÿ“ Bordeaux๐Ÿ“ Caen๐Ÿ“ Clermont-Ferrand Institut Claudius Regaud ยท Tests: Main study:, Sub-study: A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors NCT06609187Phase 11 site๐Ÿ“ Beijing Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: GNC-077 Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer NCT06105684Phase 21 site๐Ÿ“ Birmingham University of Alabama at Birmingham ยท Tests: Capecitabine Pill A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers. NCT07593820Phase 12 sites๐Ÿ“ Barcelona๐Ÿ“ Barcelona Vall d'Hebron Institute of Oncology ยท Tests: p95HER2.CAR-TECH2Me FDG PET-CT in Advanced Breast Cancer NCT07173868n/a1 site๐Ÿ“ Seoul Samsung Medical Center Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors NCT04222413Phase 12 sites๐Ÿ“ Fairway๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: Metarrestin Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer NCT05430399Phase 32 sites๐Ÿ“ Guangzhou๐Ÿ“ Hunan Sun Yat-sen University ยท Tests: utidelone, docetaxel Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer NCT04090567Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Cediranib, Ceralasertib, Olaparib The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer. NCT06851299Phase 21 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: trop2-ADC, ADC +anti-angiogenic drug, ADC + PD1 monoclonal antibody +anti-angiogenic drug A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer NCT03424005Phase 1, Phase 255 sites๐Ÿ“ Duarte๐Ÿ“ Duarte๐Ÿ“ Irvine Hoffmann-La Roche ยท Tests: Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805Phase 113 sites๐Ÿ“ Duarte๐Ÿ“ Grand Rapids๐Ÿ“ Long Island City Pfizer ยท Tests: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ๏ผšSingle-arm, Prospective, Open Clinical Study NCT06125080Phase 21 site๐Ÿ“ Wuhan Huihua Xiong ยท Tests: Utidelone, Tirelizumab, Bevacizumab Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer NCT06179303Phase 23 sites๐Ÿ“ St Louis๐Ÿ“ Chapel Hill๐Ÿ“ Seattle University of Washington ยท Tests: Abemaciclib, Anastrozole, Biospecimen Collection, Computed Tomography, Diagnostic Imaging Testing Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer NCT06706557n/a1 site๐Ÿ“ Milan European Institute of Oncology HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan NCT06236269Phase 210 sites๐Ÿ“ Badalona๐Ÿ“ L'Hospitalet de Llobregat๐Ÿ“ Barcelona SOLTI Breast Cancer Research Group ยท Tests: Sacituzumab Govitecan A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer NCT07347600n/a32 sites๐Ÿ“ Xiamen๐Ÿ“ Lanzhou๐Ÿ“ Shijiazhuang Hoffmann-La Roche ยท Tests: Inavolisib, Palbociclib, Fulvestrant A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ยท Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) NCT07648914Phase 31 site๐Ÿ“ Beijing Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-B01D1, Albumin-Bound Paclitaxel, Paclitaxel, Capecitabine Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites๐Ÿ“ Atlanta๐Ÿ“ Nashville๐Ÿ“ San Antonio Novartis Pharmaceuticals ยท Tests: GVV858, Fulvestrant, Letrozole Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors NCT04771520Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Avapritinib A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. NCT06022029Phase 116 sites๐Ÿ“ Los Angeles๐Ÿ“ Tamarac๐Ÿ“ Canton OncoNano Medicine, Inc. ยท Tests: ONM-501, Cemiplimab Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial NCT06278870Phase 31 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: disitamab vedotin, Pyrotinib, trastuzumab, Pertuzumab, taxane drug Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors NCT05969041Phase 16 sites๐Ÿ“ Darlinghurst๐Ÿ“ Randwick๐Ÿ“ Westmead Myeloid Therapeutics ยท Tests: MT-302 (A) Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) NCT05660083Phase 23 sites๐Ÿ“ Bethesda๐Ÿ“ Houston๐Ÿ“ Houston The Methodist Hospital Research Institute ยท Tests: L-NMMA A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer NCT07100106Phase 1, Phase 277 sites๐Ÿ“ Huntsville๐Ÿ“ Tucson๐Ÿ“ Duarte Genentech, Inc. ยท Tests: GDC-4198, Giredestrant, Abemaciclib A Phase 1 Study of LNCB74 in Advanced Solid Tumors NCT06774963Phase 114 sites๐Ÿ“ Newport Beach๐Ÿ“ Edgewood๐Ÿ“ Boston NextCure, Inc. ยท Tests: LNCB74 An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial NCT06999798Phase 11 site๐Ÿ“ Rochester Mayo Clinic ยท Tests: Diagnostic Mammography, Resection, Ultrasound Imaging, Twinkling Marker Placement Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer NCT07049133n/a1 site๐Ÿ“ Milan European Institute of Oncology ยท Tests: T-DXd toxicity marker identification
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy